Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by University of Malaya.
Recruitment status was  Recruiting
Information provided by (Responsible Party):
University of Malaya
ClinicalTrials.gov Identifier:
First received: June 20, 2012
Last updated: June 21, 2012
Last verified: June 2012

Patients who will be scheduled for intravitreal injection of Ranibizumab or Bevacizumab will be recruited in this prospective self-controlled trial. Fundus photography will carried out at baseline immediately before injection and at 3, 7 days and 30 days after the first injection. Using image analysis software, measurements summarized as the central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE).

Null Hypothesis: There is no significant difference between arteriolar/venular diameter before and after injection of intravitreal ranibizumab/bevacizumab in the treated and untreated eye

Condition Intervention
Age Related Macular Degeneration
Drug: Intravitreal Ranibizumab
Drug: Intravitreal bevacizumab

Study Type: Interventional
Official Title: Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter

Resource links provided by NLM:

Further study details as provided by University of Malaya:

Estimated Enrollment: 30
Study Start Date: April 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Intravitreal Ranibizumab
    Other Name: Lucentis
    Drug: Intravitreal bevacizumab
    Other Name: Avastin

Ages Eligible for Study:   20 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

• Patients who wish and need bevacizumab or ranibizumab treatment for underlying disease

Exclusion Criteria:

  • History of previous systemic or ocular Anti-VEGF therapy
  • History of previous intravitreal injection with any drug
  • Intraocular pressure ≥ 22
  • Glaucoma
  • History or presence of thromboembolic events
  • Un-controlled blood pressure
  • Blood donation during the previous 3 weeks
  • Relevant media opacity of the lens
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01626339

Contact: Mohammadreza Peyman, MD 0060173387260 ext 1 drmpeyman@yahoo.com
Contact: Visvaraja Subrayan, Prof d.visva@hotmail.com

University of Malaya Medical Center Recruiting
Kuala Lumpur, Malaysia, 59100
Contact: Mohammadreza Peyman, MD    0060173387260    drmpeyman@yahoo.com   
Sponsors and Collaborators
University of Malaya
  More Information

Responsible Party: University of Malaya
ClinicalTrials.gov Identifier: NCT01626339     History of Changes
Other Study ID Numbers: PPUM/MDU/300/04/03 
Study First Received: June 20, 2012
Last Updated: June 21, 2012
Health Authority: Malaysia: Institutional Review Board

Keywords provided by University of Malaya:
Anti vascular endothelial growth factor
retinal vessels

Additional relevant MeSH terms:
Macular Degeneration
Eye Diseases
Retinal Degeneration
Retinal Diseases
Endothelial Growth Factors
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 22, 2016